| Group A (n=540, 67%)
| Group B(n=265,33%)
| p-value
|
Age (years)
| 6.39
| 5.9
| 0.015
|
Sex-ratio (M/F)
| 1.39
| 1.6
| 0.362
|
The normalized daily dose (mg/kg/day)
| 27.33
| 27.58
| 0.119
|
Initial Valproic Acid C0, (μg/mL), median [limits]
| 46.77
[0-142.46]
| 48.19
[0-149.6]
| <0.0001
|
Initial Valproic Acid C0, in the Therapeutic Range
| 62.78%
| 35.10%
| <0.0001
|
Subtherapeutic initial Valproic Acid C0
| 30.55%
| 57.73%
|
|
Supra-therapeutic initial Valproic Acid C0
| 6.67%
| 7.17%
|
|
Concentration/Dose ratio
| 2.14
| 1.79
| 0.0036
|
Daily dose optimization
| 79%
| 80%
| 0.81
|
The number of Valproic Acid C0 determination per patient
| 3.28
| 2.91
| 0.006
|
Follow-up duration (months)
| 22.93
| 18.2
| <0.0001
|
Adverse events
| 15.37%
| 10.94%
| 0.088
|
Anti-epileptic drugs association
| 9.63%
| 9.43%
| 0.935
|